We are live on ! Find out more
INO icon

Inovio Pharmaceuticals

110 hedge funds and large institutions have $22.2M invested in Inovio Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,018% more call options, than puts

Call options by funds: $436K | Put options by funds: $39K

46% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 13

26% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 27

15% more capital inflows, than outflows

Capital inflows: $5.68M | Capital outflows: $4.94M

5% more funds holding

Funds holding: 105 → 110 (+5)

0.12% more ownership

Funds ownership: 36.97% → 37.09% (+0.12%)

Holders
110
Holders Change
+5
Holders Change %
+4.76%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
34
Reduced
27
Closed
13
Calls
$436​K
Puts
$39​K
Net Calls
+$397​K
Net Calls Change
+$103​K

INO Hedge Fund Activity: Q1 2025 in Review

110 of the 7,493 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2025, worth a combined $22.2M — down 9.3% from $24.4M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new INO positions and 13 closed out — a net gain of 6 holders — while 34 added to existing stakes and 27 trimmed.

The largest buyer was Bank of America, adding an estimated $1.33M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $1.2M sold.

  • 110 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2025, up from 105 in Q4 2024.
  • Funds reported $22.2M of Inovio Pharmaceuticals stock for Q1 2025, down 9.3% quarter-over-quarter.
  • 19 funds opened new Inovio Pharmaceuticals positions in Q1 2025 and 13 closed out, a net change of +6 holders.
  • The largest Inovio Pharmaceuticals buyer in Q1 2025 was Bank of America, an estimated $1.33M added.
  • The largest Inovio Pharmaceuticals seller in Q1 2025 was AIGH Capital Management, an estimated $1.2M sold.

Based on aggregated 13F filings for Q1 2025.